# Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

> **NCT00228358** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 8 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Recurrent Breast Cancer
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Stage IV Breast Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor

## Interventions

- **DRUG:** ex vivo-expanded HER2-specific T cells
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** denileukin diftitox
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique

## Key facts

- **NCT ID:** NCT00228358
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228358, "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00228358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*